恩替卡韦治疗乙型肝炎肝硬化的疗效观察  

Observation of effect on Entecavir in the treatment of hepatitis B cirrhosis

作　　者：尹胜平[1,2] 葛善飞[1,2] 蒋茵[1,2] 

机构地区：[1]广西医科大学第四附属医院 [2]柳州市工人医院感染科,广西柳州545005

出　　处：《中国医药导报》2012年第7期57-58,63,共3页China Medical Herald

摘　　要：目的观察恩替卡韦治疗乙型肝炎肝硬化的临床疗效。方法将88例乙型肝炎肝硬化患者随机分为治疗组和对照组,各44例。对照组给予常规保肝及对症治疗,治疗组在常规治疗基础上加恩替卡韦0.5 mg/d,疗程1年。观察两组患者肝功能、Child-Pugh评分、HBV DNA、肝纤维化指标(HA、LN、PⅢP、Ⅳ-C)的变化。结果治疗组总有效率为95.5%,对照组总有效率为63.6%,治疗组总有效率显著高于对照组(P<0.01)。两组患者治疗前后肝纤维化指标(HA、LN、PⅢP、Ⅳ-C)、肝功能及Child-Pugh评分比较差异均有统计学意义(P<0.05),治疗组患者治疗12周后肝纤维化指标、肝功能、Child-Pugh评分及HBV DNA均较对照组显著改善(P<0.05)。结论恩替卡韦治疗乙型肝炎肝硬化疗效显著,不良反应少,耐受性好,是一种有效、安全且理想的药物。Objective To observe clinical effect of hepatitis B cirrhosis treated with Entecavir.Methods 88 patients with hepatitis B cirrhosis were divided into treatment group（44 patients） and control group（44 patients） randomly.The control group received conventional liver-protecting and symptomatic treatment only,while the treatment group received additional Entecavir（0.5 mg/d,one year course）.The liver function,Child-Pugh grade,HBV DNA and liver fibrosis markers（HA,LN,PⅢP and Ⅳ-C） of two groups were observed.Results The total effective rate of treatment group（95.5%） was higher than control group（63.6%）（P 〈 0.01）.After treatment,the liver fibrosis markers（HA,LN,PⅢP and Ⅳ-C）,liver function and Child-Pugh grade in both groups were significantly improved（P 〈 0.05）.There were significant differences of liver fibrosis markers（HA,LN,PⅢP and Ⅳ-C）,liver function,Child-Pugh grade and HBV DNA between treatment group and control group after treatment（P 〈 0.05）.Conclusion Entecavir has significant clinical effect,low adverse reaction and good tolerance in treating patients with hepatitis B cirrhosis

关 键 词：乙型肝炎肝硬化 恩替卡韦 疗效 

分 类 号：R575.2[医药卫生—消化系统]